Introduction and Objective: Prior research has shown a link between marital quality and HbA1c in adults with T1D, however, little is known about how parenting impacts glycemic control, including CGM metrics. The aim of the current study was to investigate whether relationship and parenting status impact glycemic outcomes in adults with T1D. Emotional distress was investigated as a secondary outcome.Methods: A total of 208 participants with T1D (mean [range] age = 45.60 [18-84] years, 53.40% female, 74.5% married or partnered, 30.8% with children ≤18) were recruited from four diabetes centers. Glycemic (HbA1c, CGM time in range [TIR], percent time <70 mg/dL) and emotional (Generalized Anxiety Disorder-7, Patient Health Questionnaire-8, Perceived Stress Survey) outcomes were assessed. Analysis of covariance (ANCOVA) was used to examine the impact of relationship and parenting status on glycemic and emotional outcomes while controlling for age and gender.Results: Single participants (N=53) spent more time in hypoglycemia compared to married/partnered participants (N=155) after controlling for age, gender, and parenting, F (1, 191) = 5.38, p =.02. While there was no main effect of parenting on any outcome, there was a significant interaction between relationship status and parenting on HbA1c, F (1, 196) = 5.29, p =.02, and TIR, F (1, 191) = 6.45, p =.01. Single parents (N=16) had higher HbA1c and lower TIR than single adults without children and married/partnered participants with/without children. Neither relationship status nor parenting was associated with emotional distress.Conclusion: These findings suggest that adults with T1D who are single, and particularly those who are single parents, have poorer glycemic control than those in a relationship. Emotional distress did not differ by relationship or parenting status. Further research is needed to confirm these findings and suggest possible mechanisms.
M.S. Zuniga-Kennedy: None. L.M. Fonseca: None. Y.C. Kudva: Advisory Panel; Novo Nordisk, Vertex Pharmaceuticals Incorporated, Tandem Diabetes Care, Inc. Research Support; Dexcom, Inc., Insulet Corporation. S. Rizvi: None. R.S. Weinstock: Research Support; Amgen Inc, Eli Lilly and Company, Tandem Diabetes Care, Inc, Diasome Pharmaceuticals, Insulet Corporation, MannKind Corporation, Dexcom, Inc. J.D. Bulger: None. R.E. Pratley: Consultant; AbbVie Inc. Stock/Shareholder; Altanine, Inc. Consultant; Amgen Inc, AstraZeneca. Other Relationship; Bayer AG, Bayer Pharmaceuticals, Inc, Biomea Fusion. Consultant; Boehringer-Ingelheim. Other Relationship; Carmot Therapeutics, Inc, Corcept Therapeutics, Dompé, Eli Lilly and Company, Endogenex. Consultant; Endogenex. Other Relationship; Fractyl Health, Inc., Gasherbrum Bio, Inc. Consultant; Genprex, Getz Pharma, Hanmi Pharm. Co., Ltd, Intas Pharmaceuticals Ltd, Lexicon Pharmaceuticals, Inc, Lilly USA LLC. Speaker’s Bureau; Lilly USA LLC. Other Relationship; Metavention, Novo Nordisk, Novo Nordisk. Speaker’s Bureau; Novo Nordisk. Other Relationship; Pfizer Inc, Poxel SA. Consultant; Regeneron Pharmaceuticals. Other Relationship; Sanofi. Consultant; Scholar Rock. Other Relationship; Sun Pharmaceutical Industries Ltd. M.R. Rickels: Consultant; Vertex Pharmaceuticals Incorporated, Sernova, Corp. Research Support; Dompé, Tandem Diabetes Care, Inc. Consultant; Novo Nordisk. L. Germine: Stock/Shareholder; Intelerad Medical Systems. N. Chaytor: None.
National Institute of Health – National Institute of Diabetes, Digestive and Kidney Diseases, NIH- NIDDK (R01-DK121240-01)
Source link
Leave a Reply